Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15142MR)

This product GTTS-WQ15142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases, Pemphigus vulgaris (PV) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15142MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3069MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ14206MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ3738MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ9870MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ6519MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ13435MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ3028MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ14085MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-421
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW